First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM)
Year: 2006
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: R. Plummer, P. Lorigan, J. Evans, N. Steven, M. Middleton, R. Wilson, K. Snow, R. Dewji, H. Calvert
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W1877440701
